Company / R&D per Share
NewAmsterdam Pharma Co N.V. R&D per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.20
FY2025
5-year range
$1.20 / $4.57
FY2021-FY2025
Trend
-25.4%
vs FY2024
Sector context
#138 of 204
Health Care
What the data says
At $1.20, NewAmsterdam Pharma Co N.V.'s r&d per share ranks #138 of 204 in the Health Care sector. R&D per Share has declined for 3 consecutive years, from $4.57 in FY2022 to $1.20 in FY2025.
Based on SEC 10-K filings.
1.20 in FY2025 with a 3-year CAGR of -36.0%.
Declined from $1.94 to $1.20 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -36.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#138 of 204 in Health CareTop 68% of 204This company $1.20 Sector average $34.99
▼
-96.6% below sector average
Key checks
Key Insights
- NewAmsterdam Pharma Co N.V.'s r&d per share has declined for 3 consecutive years.
- In FY2025, r&d per share decreased 25.4% year-over-year.
- Ranks #138 out of 204 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.20 | -25.4% |
| FY2024 | $1.60 | -17.3% |
| FY2023 | $1.94 | -57.6% |
| FY2022 | $4.57 | +73.3% |
| FY2021 | $2.64 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026